TAMOXIFEN AS A POTENTIAL TREATMENT OF GLIOMA

Cerebral gliomas have a poor survival time even after multimodal treat ment, because of the unavoidable recurrence of tumor. Several trials w ith a combination of old and new chemotherapics have been performed, b ut survival time remains generally less than 12 months. Tamoxifen (TAM ) has recently been shown to inhibit the growth rate of established an d low-passage human glioma cell lines. Furthermore, this drug has enab led stabilization of the clinical and radiographic picture in selected patients with recurrent glioma. Here we review published data to disc uss a potential role of TAM in the multimodal postoperative treatment of cerebral gliomas. [(C) 1998 Lippincott Williams & Wilkins.].